UNSPSC 51284711: Midecamycin acetate

This classification denotes a leucomycin and macrolides with the molecular formula C45H71NO17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T48CPS7U2, chemically known as leucomycin v, 3b,9-diacetate 3,4b-dipropanoate, but more generally known as midecamycin acetate, which bears US NIH Compound Identifier 5282188. European Medicines Agency schedules midecamycin acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08951MIG.

Most nations, for tariff purposes, schedule midecamycin acetate under HS 29419000. SMILES: CCC(=O)O[C@@H]1CC(=O)O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C.

UNSPSC 51284711 Midecamycin acetate is a Commodity code for a specific macrolide antibiotic pharmaceutical product. State and local governments procure this and related antibiotics through piggyback contracts and competitive bidding processes, typically as part of warehouse pharmaceutical supply agreements or emergency preparedness stockpiling. The recent opportunities in the dataset show state health departments and county health systems using cooperative purchasing vehicles and IFBs to acquire pharmaceutical inventories that support clinical operations, emergency response, and community health programs.

Activity under this code reflects a mix of state departments of health and county health systems. Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC in August 2026, though the products in that award (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) diverge from the Midecamycin acetate code itself, suggesting state and local procurement offices may tag related pharmaceutical supply agreements with broader or adjacent UNSPSC codes. Recent solicitations appear concentrated in Florida and Illinois. Seminole County, Florida issued an IFB in June 2026 (due July 26, 2026, though the source lists an erroneous 2023 date) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, awarded on a fixed-fee basis with an initial two-year term and one-year renewal option. The Illinois contract, valued at $2,999,999.11 over three years, was awarded through an IFB process with no set-aside or preference program utilization.